PMID- 29874469
OWN - NLM
STAT- MEDLINE
DCOM- 20190326
LR  - 20231213
IS  - 1208-6002 (Electronic)
IS  - 0829-8211 (Linking)
VI  - 96
IP  - 6
DP  - 2018 Dec
TI  - MiR-154 inhibits the growth of laryngeal squamous cell carcinoma by targeting 
      GALNT7.
PG  - 752-760
LID - 10.1139/bcb-2018-0047 [doi]
AB  - MicroRNAs are critical regulators of the development and progression of laryngeal 
      squamous cell carcinoma (LSCC). However, the role of microRNA-154 (miR-154) in 
      the development and progression of LSCC has not been clarified. We found that 
      down-regulated miR-154 expression in LSCC tissues was associated with poorer 
      prognosis in LSCC patients. MiR-154 over-expression inhibited the proliferation, 
      clonogenicity, and migration of LSCC cells and induced cell cycle arrest, which 
      were reversed by miR-154 inhibition. MiR-154 targeted GALNT7 expression by 
      reducing GALNT7-regulated luciferase activity in LSCC cells while up-regulating 
      GALNT7 mRNA transcription in LSCC tissues and cells. GALNT7 silencing 
      significantly attenuated the proliferation, clonogenicity, and migration of LSCC 
      cells and induced cell cycle arrest. Finally, intravenous treatment with 
      lentivirus for miR-154, but not scrambled control miRNA, significantly restrained 
      the growth of implanted LSCC Hep-2 tumors and decreased the tumor mass by 
      reducing GALNT7 expression in mice. Therefore, miR-154 may serve as a novel 
      prognostic marker and therapeutic target for LSCC.
FAU - Niu, Jun-Tao
AU  - Niu JT
AD  - a Department of Otorhinolaryngology, Head and Neck Surgery, the Second Hospital, 
      Tianjin Medical University, Tianjin, 300211, China.
FAU - Zhang, Li-Jun
AU  - Zhang LJ
AD  - b Basic Medical Institute, Tianjin Medical University, Tianjin, 300000, China.
FAU - Huang, Yong-Wang
AU  - Huang YW
AD  - a Department of Otorhinolaryngology, Head and Neck Surgery, the Second Hospital, 
      Tianjin Medical University, Tianjin, 300211, China.
FAU - Li, Chao
AU  - Li C
AD  - a Department of Otorhinolaryngology, Head and Neck Surgery, the Second Hospital, 
      Tianjin Medical University, Tianjin, 300211, China.
FAU - Jiang, Ning
AU  - Jiang N
AD  - c Department of Urology, Tianjin Institute of Urology, the Second Hospital, 
      Tianjin Medical University, Tianjin, 300211, China.
FAU - Niu, Yuan-Jie
AU  - Niu YJ
AD  - c Department of Urology, Tianjin Institute of Urology, the Second Hospital, 
      Tianjin Medical University, Tianjin, 300211, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20180606
PL  - Canada
TA  - Biochem Cell Biol
JT  - Biochemistry and cell biology = Biochimie et biologie cellulaire
JID - 8606068
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN154 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - EC 2.4.1.- (N-Acetylgalactosaminyltransferases)
SB  - IM
RIN - Biochem Cell Biol. 2023 Apr 1;101(2):197. PMID: 36876851
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/*pathology
MH  - Cell Cycle Checkpoints
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/metabolism/*pathology
MH  - Male
MH  - MicroRNAs/*genetics/metabolism
MH  - Middle Aged
MH  - N-Acetylgalactosaminyltransferases/*deficiency/genetics/metabolism
MH  - RNA, Messenger/antagonists & inhibitors/genetics/metabolism
MH  - Polypeptide N-acetylgalactosaminyltransferase
OTO - NOTNLM
OT  - GALNT7
OT  - carcinome epidermoide du larynx
OT  - croissance
OT  - growth
OT  - laryngeal squamous cell carcinoma
OT  - miR-154
EDAT- 2018/06/07 06:00
MHDA- 2019/03/27 06:00
CRDT- 2018/06/07 06:00
PHST- 2018/06/07 06:00 [pubmed]
PHST- 2019/03/27 06:00 [medline]
PHST- 2018/06/07 06:00 [entrez]
AID - 10.1139/bcb-2018-0047 [doi]
PST - ppublish
SO  - Biochem Cell Biol. 2018 Dec;96(6):752-760. doi: 10.1139/bcb-2018-0047. Epub 2018 
      Jun 6.